Literature DB >> 9883547

A general framework for random effects survival analysis in the Cox proportional hazards setting.

D J Sargent1.   

Abstract

The use of random effects modeling in statistics has increased greatly in recent years. The introduction of such modeling into event-time analysis has proceeded more slowly, however. Previously, random effects models for survival data have either required assumptions regarding the form of the baseline hazard function or restrictions on the classes of models that can be fit. In this paper, we develop a method of random effect analysis of survival data, the hierarchical Cox model, that is an extension of Cox's original formulation in that the baseline hazard function remains unspecified. This method also allows an arbitrary distribution for the random effects. We accomplish this using Markov chain Monte Carlo methods in a Bayesian setting. The method is illustrated with three models for a dataset with times to multiple occurrences of mammory tumors for 48 rats treated with a carcinogen and then randomized to either treatment or control. This analysis is more satisfying than standard approaches, such as studying the first event for each subject, which does not fully use the data, or assuming independence, which in this case would overestimate the precision.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9883547

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  19 in total

1.  A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron.

Authors:  E H Cox; C Veyrat-Follet; S L Beal; E Fuseau; S Kenkare; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

2.  Assessing the impact of managed-care on the distribution of length-of-stay using Bayesian hierarchical models.

Authors:  D Stangl; G Huerta
Journal:  Lifetime Data Anal       Date:  2000-06       Impact factor: 1.588

Review 3.  Design and analysis of group-randomized trials: a review of recent methodological developments.

Authors:  David M Murray; Sherri P Varnell; Jonathan L Blitstein
Journal:  Am J Public Health       Date:  2004-03       Impact factor: 9.308

4.  USING PROFILE LIKELIHOOD FOR SEMIPARAMETRIC MODEL SELECTION WITH APPLICATION TO PROPORTIONAL HAZARDS MIXED MODELS.

Authors:  Ronghui Xu; Florin Vaida; David P Harrington
Journal:  Stat Sin       Date:  2009-04       Impact factor: 1.261

Review 5.  Kaplan-Meier Survival Analysis Overestimates the Risk of Revision Arthroplasty: A Meta-analysis.

Authors:  Sarah Lacny; Todd Wilson; Fiona Clement; Derek J Roberts; Peter D Faris; William A Ghali; Deborah A Marshall
Journal:  Clin Orthop Relat Res       Date:  2015-11       Impact factor: 4.176

6.  Conditional Akaike information under generalized linear and proportional hazards mixed models.

Authors:  M C Donohue; R Overholser; R Xu; F Vaida
Journal:  Biometrika       Date:  2011-07-13       Impact factor: 2.445

7.  Characterizing durations of heroin abstinence in the California Civil Addict Program: results from a 33-year observational cohort study.

Authors:  Bohdan Nosyk; M Douglas Anglin; Mary-Lynn Brecht; Viviane Dias Lima; Yih-Ing Hser
Journal:  Am J Epidemiol       Date:  2013-02-27       Impact factor: 4.897

8.  Mixed effect Poisson log-linear models for clinical and epidemiological sleep hypnogram data.

Authors:  Bruce J Swihart; Brian S Caffo; Ciprian M Crainiceanu; Naresh M Punjabi
Journal:  Stat Med       Date:  2012-01-13       Impact factor: 2.373

9.  Characterizing retention in HAART as a recurrent event process: insights into 'cascade churn'.

Authors:  Bohdan Nosyk; Lillian Lourenço; Jeong Eun Min; Dimitry Shopin; Viviane D Lima; Julio S G Montaner
Journal:  AIDS       Date:  2015-08-24       Impact factor: 4.177

10.  Characterizing longitudinal health state transitions among heroin, cocaine, and methamphetamine users.

Authors:  B Nosyk; L Li; E Evans; D Huang; J Min; T Kerr; M L Brecht; Y I Hser
Journal:  Drug Alcohol Depend       Date:  2014-04-08       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.